TSS
BCRX icon

Two Sigma Securities’s BioCryst Pharmaceuticals BCRX Stock Holding History

Two Sigma Securities’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,119
Closed -$51.4K – 2983
2024
Q1 		$51.4K Buy
+10,119
New +$56.9K ﹤0.01% 2566
2023
Q2 		– Sell
-25,030
Closed -$209K – 2785
2023
Q1 		$209K Buy
+25,030
New +$241K ﹤0.01% 2060
2021
Q1 		– Sell
-10,194
Closed -$76K – 892
2020
Q4 		$76K Buy
+10,194
New +$52.6K ﹤0.01% 1531
2020
Q2 		– Sell
-20,058
Closed -$40K – 1363
2020
Q1 		$40K Buy
+20,058
New +$55.2K ﹤0.01% 1196
2017
Q2 		– Sell
-10,396
Closed -$87K – 867
2017
Q1 		$87K Buy
+10,396
New +$72.3K 0.02% 765

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Securities's BCRX Position: Q2 2024 in Review

Two Sigma Securities sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 10,119 shares — an estimated $51.4K sold.

Two Sigma Securities first reported a position in BCRX in Q1 2017 and held it in 5 quarters. The position peaked at $209K in Q1 2023. 241 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

  • Two Sigma Securities reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Two Sigma Securities sold 10,119 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $51.4K.
  • Two Sigma Securities first reported a position in BioCryst Pharmaceuticals in Q1 2017 and held it in 5 quarters.
  • Two Sigma Securities's BioCryst Pharmaceuticals position peaked at $209K in Q1 2023.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on Two Sigma Securities's 13F filing for Q2 2024, filed 14 Aug 2024.